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A B S T R A C T
Glioblastoma is the most common malignant brain tumor, which, despite combined radio- and
chemotherapy, recurs and is invariably fatal for affected patients. Members of the sphingolipid (SL)
family are potent effectors of glioma cell proliferation. In particular sphingosine-1-phosphate (S1P) and
the corresponding G protein-coupled S1P receptors transmit proliferative signals to glioma cells. To
investigate the contribution to glioma cell proliferation we inhibited the ﬁrst step of de novo SL synthesis
in p53wt and p53mut glioma cells, and interfered with S1P signaling speciﬁcally in p53wt U87MG cells.
Subunit silencing (RNAi) or pharmacological antagonism (using myriocin) of serine palmitoyltransferase
(SPT; catalyzing the ﬁrst committed step of SL biosynthesis) reduced proliferation of p53wt but not
p53mut GBM cells. In U87MG cells these observations were accompanied by decreased ceramide,
sphingomyelin, and S1P content. Inhibition of SPT upregulated p53 and p21 expression and induced an
increase in early and late apoptotic U87MG cells. Exogenously added S1P (complexed to physiological
carriers) increased U87MG proliferation. In line, silencing of individual members of the S1P receptor
family decreased U87MG proliferation. Silencing and pharmacological inhibition of the ATP-dependent
cassette transporter A1 (ABCA1) that facilitates S1P efﬂux in astrocytes attenuated U87MG growth.
Glyburide-mediated inhibition of ABCA1 resulted in intracellular accumulation of S1P raising the
possibility that ABCA1 promotes S1P efﬂux in U87MG glioma cells thereby contributing to inside-out
signaling. Our ﬁndings indicate that de novo SL synthesis, S1P receptor-mediated signaling, and ABCA1-
mediated S1P efﬂux could provide pharmacological targets to interfere with glioma cell proliferation.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Glioblastoma (GBM; astrocytoma grade IV) tumors are the most
common type of primary brain tumors occurring in adult patients.
The effectiveness of treatments is limited due to the high
proliferative potential and the diffusely inﬁltrating properties of
the tumor [1,2].
Sphingolipid (SL) metabolites represent a major class of
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[3]. Therefore it is not surprising that dysregulated SL metabolism
contributes to cancer progression and could provide a pharmaco-
logical target to develop new chemotherapeutics [4]. The central
metabolite of SL turnover is ceramide (Cer). In the ﬁrst rate-
limiting step of de novo synthesis serine palmitoyltransferase
(SPT) catalyzes the condensation of serine and palmitoyl-CoA and a
series of subsequent reactions including Cer synthases (CerS)
generate Cer [3,5]. Alternatively Cer can be generated by hydrolysis
of sphingomyelin (SM) via the action of sphingomyelinases
(SMases) or from glycosphingolipids.
Members of the CerS family catalyze the formation of Cer from
sphingosine and acyl-CoA substrates. This family of enzymes takes
a unique role in SL metabolism in that they regulate de novo SL
synthesis and the recycling of free sphingosine from degradation ofle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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CerS is able to synthesize Cer species with characteristic acyl-chain
lengths [7]. De-acylation of Cer yields sphingosine, which can be
phosphorylated (via sphingosine kinase 1 or 2; SK1/2) to yield
sphingosine-1-phosphate (S1P). Thus, Cer, sphingosine, and S1P
are readily interconvertible resulting in a highly dynamic SL pool.
This is of importance since the ‘balance’ of this SL rheostat
determines cell fate [7]. Cer typically induces growth arrest and/or
apoptosis in response to stress signals while S1P inhibits apoptosis
and induces cell proliferation [8]. Therefore, tuning of the SL
rheostat in favor of S1P results in a cellular survival beneﬁt for
tumor cells whereas Cer generation inhibits tumorigenesis [4].
S1P-mediated signaling is elicited by ﬁve G protein-coupled
receptors termed S1P1–5. By activation of speciﬁc downstream
effector molecules, these receptors induce a variety of cellular
responses many of them central to tumor biology [8] including cell
transformation, survival, migration, metastasis, and angiogenesis
[3,8–11]. Accumulating evidence suggests that S1P, SK, and S1P
receptors are central players that regulate GBM growth, migration,
and invasion via outside-in or inside-out signaling [12]. Exoge-
nously added S1P is a potent glioblastoma mitogen and enhances
glioblastoma invasiveness [13–17]. Microarray analyses suggest
that upregulation of proteases in response to exogenous S1P could
be key to invasive properties of glioblastoma cells [18]. Only
recently a systematic shift in SL metabolism favoring S1P over Cer
generation in GBM was demonstrated [19]. Furthermore inhibition
of S1P production in GBM cells resulted in decreased angiogenesis
of co-cultured endothelial cells [19].
S1P receptors are expressed in GBM tissues and cell lines
[20,21]. Overexpression of S1P1 correlates with high invasive
potential of CD133+ GBM cells [15,16]. S1P2 inhibits GBM cell
migration [22–24] but increases invasive potential [24]. SK1 is
upregulated in GBM and expression levels are linked to reduced
survival [20]. Concomitantly it was shown that interleukin-1-
mediated upregulation of SK1 increases growth rates and
invasiveness of GBM cells [25]. Accordingly, pharmacological
inhibition of SK induces apoptosis of GBM cells in vitro [26],
reduces GBM xenograft growth in vivo [27], and increases the anti-
proliferative potential of temozolomide in glioma cell cultures
[28].
Many cell types are able to secrete S1P and evidence suggests
that ATP-binding cassette (ABC) transporters are involved in this
pathway. S1P release from mast cells and platelets is mediated by
ABC transporters [29,30]. In astrocytes ABCA1 is responsible for
S1P export [31]. Pharmacological compounds that shift the SL
pattern toward a more anti-proliferative phenotype could be
suitable co-adjuvants in combination with common chemother-
apeutics [32]. Therefore the present in vitro study aimed at
investigating the contribution of the committed step of de novo SL
biosynthesis, individual members of the S1P receptor family, and
the putative S1P efﬂux pump ABCA1 to GBM cell proliferation.
2. Materials and methods
2.1. Materials
Cell culture supplies were from Gibco (Invitrogen, Vienna,
Austria), PAA Laboratories (Linz, Austria) and Costar (Vienna). 4,40-
Diisothiocyanostilbene-2,20-disulfonic acid (DIDS), SuperScript III
Reverse Transcriptase and Oligofectamine were from Invitrogen
(Vienna). Random Hexamer Primer was from Thermo Scientiﬁc
(MA, USA). Myriocin, 25-hydroxycholesterol (25-OHcholesterol),
glyburide, bovine serum albumin (BSA), monoclonal anti-b-actin,
and horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG
were from Sigma (Vienna, Austria). 24-OHcholesterol was from
Steraloids (Newport, CT). TO901317 was from Cayman Europe(Tallin, Estonia). S1P, anti-S1P2 (H-64), anti-S1P5 (H-88), anti-p21
(187), anti-SPTLC1 (H-300; a catalytic subunit of SPT), and HRP-
labeled goat anti-mouse IgG were from Santa Cruz (Santa Cruz
Biotechnology, CA, USA). Anti-S1P1 (AB-236) was from Assay Bio
Tech (Antibodies-Online, Aachen, Germany), anti-S1P3 (ab74477)
was from Abcam (Cambridge, UK), and anti-p53 (clone DO-7) was
from DakoCytomation (Gostrup, DK). SuperSignal Western blot
detection reagent kit was from Pierce (Thermo Scientiﬁc, MA, USA)
and ECL Plus Western Blotting Reagents were form Amersham
Biosciences (Vienna). RNeasy Plus Kit, QuantiFast SYBR Green PCR
kit, QuantiTect primer assays hydroxymethylbilane synthase
(Hs_HMBS_1_SG), S1P1 (Hs_S1PR1_1_SG), S1P2 (Hs_S1PR2_1_SG),
S1P3 (Hs_S1PR3_1_SG), S1P5 (Hs_S1PR5_1_SG), ABCA1 (Hs_AB-
CA1_1_SG), SPT (Hs_SPTLC1_1_SG, Hs_SPTLC2_1_SG, and Hs-
SPTLC3_2_SG), were from Qiagen (Hilden, Germany). The siRNAs
targeting SPTLC1 (Hs_SPTLC1_12 and Hs_SPTLC1_13), SPTLC2
(Hs_SPTLC2_1 and Hs_SPTLC2_6), SPTLC3 (Hs_SPTLC3_2 and
Hs_SPTLC3_6), S1P1 (Hs_S1PR1_5), S1P2 (Hs_S1PR2_6), S1P3
(Hs_S1PR3_6), S1R5 (Hs_S1PR5_6), and ABCA1 (Hs_ABCA1_2 and
Hs_ABCA1_5) were also from Qiagen. Non-targeting siRNA (‘siScr’)
was from Dharmacon (Thermo Scientiﬁc, MA, USA). Guava
ViaCount Reagent was from Merck Millipore (Darmstadt,
Germany).
2.2. Cells and culture conditions
The human glioma cell lines U87MG and U251MG were
purchased from CLS-Cell line services, Germany or ATTC, LGC
Standards, Germany and maintained in DMEM/high glucose
supplemented with 10% fetal calf serum (FCS) and 2% penicillin/
streptomycin at 37 8C under 5% CO2. Establishment and culture of
GM133 cells has been previously described in detail [33]. Primary
GBM2 were established from glioblastoma multiforme tissue
obtained during surgery and diagnosed according to the WHO
classiﬁcation. The p53 status of GBM2 cells was sequenced and
described recently [34]. The protocol was approved by the local
ethical review boards. Cells were cultured in DMEM/high glucose
supplemented with 10% FCS and 2% penicillin/streptomycin at
37 8C under 5% CO2 and used up to passage 10.
2.3. RNA interference
Cells were seeded at 50,000 cells per well into 12 well plates
and grown for 24 h. Transfection of siRNA (20 nM) was performed
with Oligofectamine according to the manufacturer’s suggestions
(Invitrogen). Untreated cells (control) and cells transfected with
Oligofectamine alone (mock) or scrambled siRNA (siScr) were used
as controls.
2.4. Western blot analysis
For immunoblotting, protein concentration of whole cell
extracts and mouse brain lysates was measured using the Bradford
protein assay. Equal protein aliquots were loaded, separated on
SDS-PAGE under reducing conditions, transferred to PVDF
membranes and probed with speciﬁc primary antibodies as
described in Materials. Immunoreactive bands were detected with
HRP-conjugated secondary antibodies. Protein expression was
visualized using ECL reagents. Membranes were stripped and re-
probed for b-actin (1:5000).
2.5. Proliferation
Cells were seeded at 50,000 per well into 12 well culture plates,
grown for 24 h and transfected with speciﬁc siRNA (20 nM). At the
indicated time points cells were trypsinized and the cell number
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2.6. Treatment with pharmacological inhibitors
Cells (50,000) were plated into 12 well and grown for 24 h.
Then, myriocin (in DMSO; 1 and 5 mM; Ref. [35]) and DMSO as
vehicle control (0.05%) was added daily in medium without
serum. For treatment with glyburide (200 mM; Ref. [30]) and DIDS
(400 mM; Ref. [36]), U87MG cells were seeded at 100,000 cells per
well into 12 well culture plates and allowed to attach overnight.
The cells were serum starved for 24 h and treated with glyburide or
DIDS, and the corresponding vehicle controls as indicated. Cell
numbers were determined as described above.
2.7. SL analysis
Three days post-SPTLC1 silencing or overnight treatment with
myriocin (1 mM serum-free) cells were harvested and sonicated in
cold phosphate buffered saline (PBS; pH 7.4). Samples were mixed
with three volumes of chloroform/methanol (2:1; v/v) with Cer17:0
and SM17:0 as internal standards (Avanti Polar Lipids, Alabaster,
USA). For SL analysis lipid extracts were subjected to a mild alkaline
hydrolysis step by adding 400 ml 1 N NaOH in methanol/CHCl3/H2O
(10:5:1; v/v/v) and incubated for 45 min at room temperature.
Samples were then neutralized by adding 150 ml 1 M acetic acid
and 400 ml 0,5 M EDTA. After adding 1 ml CHCl3, samples were
vortexed, centrifuged, and the upper aqueous layer was removed.
Then, 700 ml H2O were added and after vortexing the aqueous
phase was removed again and the lower organic layer was dried
under N2. Lipids were separated on a C-18 UPLC-column and
analyzed with a QTOF-MS system as described [37]. Data analysis
was performed using the Lipid Data Analyzer Software [38].
2.8. Quantiﬁcation of S1P
For S1P measurements cells were seeded in 21 cm2 Petri dishes.
When approximately 80% conﬂuent, cells were treated with
myriocin (1 mM, overnight in serum) or glyburide (500 mM for
10 h and 200 mM for 14 h, serum-free). DMSO was used as vehicle
control. Quantiﬁcation of intracellular S1P was performed with a
commercially available ELISA kit (Echelon Biosciences, UT, US)
according to the manufacturer’s suggestions. For quantitative
analysis of samples a nonlinear regression model (as suggested by
the manufacturer) was used and data were normalized to protein
content.
2.8.1. Annexin V/propidium iodide staining
Cells were transfected with siRNA or treated with 1 mM
myriocin as described above. On day ﬁve cells were harvested
and stained using the FITC Annexin V Apoptosis Detection Kit 1 (BD
Biosciences, USA) as recommended by the manufacturer. Brieﬂy,
cells were washed in cold PBS and incubated for 15 min at room
temperature in the dark in 100 ml of 1 binding buffer containing
5 ml of Annexin V FITC and 5 ml of propidium iodide (PI). Flow
cytometric analyses were performed on Guava EasyCyte 8
(Millipore, Billerica, MA, USA) and analyzed using ModFit (Verity
Software House). To set up ﬂuorescent compensation and gating
for the detection of early and late apoptosis, unstained and single
stained positive controls treated with staurosporine (Enzo Life
Sciences, Switzerland; 1 mM, 4 h) or H2O2 (3 mM, 4 h) were used.
2.9. RT-qPCR
Cells were transfected with siRNA, lysed, and RNA extracts were
collected at the indicated time points. Total RNA was isolated usingthe RNeasy Plus Kit. Aliquots of three mg of total RNA were reverse
transcribed using SuperScript III Reverse Transcriptase and
random hexamer primers according to the manufacturer’s
instructions (Invitrogen). RT-qPCR was performed with an Applied
Biosystems 7900HT Fast Real Time PCR System, the QuantiFast
SYBR Green PCR kit and QuantiTect Primer Assays. HMBS or
hypoxanthine phosphoribosyltransferase (HPRT) was used as
housekeeping gene.
2.9.1. S1P-enrichment of high density lipoprotein (HDL) or BSA
Human HDL (4 mg protein/ml; isolated as described [39]) or
fatty-acid free BSA (4 mg/ml) were incubated with S1P (50 mg) on a
rotating wheel for 4 h at 37 8C. S1P content was determined as
described above.
2.10. S1P treatment
U87MG cells were seeded at 40,000 cells per well into 12 well
culture plates and allowed to attach overnight. The cells were
serum starved for 24 h and received BSA-bound (S1P-BSA) or HDL-
bound S1P (S1P-HDL) at the indicated concentrations. S1P-BSA or
S1P-HDL was added every 24 h to overcome short half-life in the
cellular supernatant [40]. Six days after plating cells were
trypsinized and the cell number was determined with a Casy Cell
Counter.
2.11. Statistical analyses
Data are presented as mean  SD. Either Student’s t-test or
ANOVA was used for analysis of statistical signiﬁcance (using the
GraphPad Prism package). All values of p < 0.05 were considered
signiﬁcant. Statistical signiﬁcance of differences in mRNA expression
levels was analyzed using the relative expression software tool
(REST, http://www.gene-quantiﬁcation.de/rest.html) using a pair-
wise ﬁxed reallocation test [41].
3. Results
3.1. Silencing of SPTLC1 or inhibition of SPT impairs cell growth, alters
cellular SL proﬁles, and induces apoptosis
To elucidate the contribution of de novo SL synthesis to cell
proliferation, SPTLC1, a catalytic long chain base subunit of SPT
catalyzing the ﬁrst and committed step of SL synthesis, was
silenced in a panel of glioma cells. To get an indication whether the
p53 status determines the outcome of SPTLC1 silencing on cell
proliferation we used three established glioma cell lines (U87MG,
U251, and GM133) and one low passage culture (GBM2) that was
established by our group; of these cells, GM133 and U251 are
p53mut, while GBM2 and U87MG are p53wt [34]. Despite efﬁcient
knockdown of SPTLC1 protein levels in response to RNAi (Fig. 1A;
decrease of immunoreactive SPTLC1 by 60–90%; bar graphs) only
GBM2 and U87MG cells responded with reduced proliferation
(Fig. 1B). In both p53wt glioma cultures proliferation was reduced
to 45 and 50% of controls (Fig. 1B; GBM2 and U87MG, respectively).
Next, cellular Cer and SM composition was quantitated in
SPTLC1-silenced U87MG cells. LC–MS analyses revealed a total Cer
and SM content of 210 and 5269 ng/mg cell protein in untreated
U87MG glioma cells (Fig. 1C and D). The C16:0, 22:0, 24:0, and 24:1
species contributed the majority of Cer (81%) and SM (90%). In
response to SPTLC1 silencing, total Cer levels decreased by 48% in
comparison to controls (Fig. 1C; 109 vs. 210 ng/mg cell protein)
and by 36% in comparison to siScr (109 vs. 170 ng/mg cell protein).
SM concentrations (except the C24:2 species) were unaffected by
SPTLC1 silencing (Fig. 1D).
Fig. 1. Impact of SPTLC1 silencing on glioma cell proliferation and sphingolipid proﬁles. (A) At days 3 and 5 post-silencing (siSPTLC1_12 and _13) SPTLC1 expression was
analyzed by Western blotting in p53mut (GM133 and U251MG) and p53wt (GBM2 and U87MG) cells. Untreated cells (c) and cells transfected with scrambled siRNA (siScr)
were used as controls. The bar graph represents SPTLC1 optical density (OD) normalized to actin (two and four (U87MG) independent experiments). The SPTLC1/actin ratio of
untreated cells (c) was set to 1 and the mean OD ratios are displayed numerically. One representative blot is shown as inset. (B) Following knockdown (siSPTLC1_12 and _13)
of SPTLC1 cell numbers were counted at the indicated time points. Results shown represent mean  SD from triplicate experiments. Untreated cells (control) and cells
transfected with scrambled siRNA (siScr) were used as controls. *p < 0.05, **p < 0.01, ***p < 0.001 compared to siScr (one-way ANOVA). (C) Ceramide and (D) sphingomyelin
E. Bernhart et al. / Biochemical Pharmacology 96 (2015) 119–130122
Fig. 2. Impact of the SPT inhibitor myriocin on U87MG cell proliferation and sphingolipid proﬁles. (A) U87MG cell proliferation in the presence (10%) or the absence of FCS. Cell
numbers were counted 5 days post plating. (B) SPTLC1 expression in control (c), vehicle (vc), and myriocin-treated cells was analyzed by Western blotting. The bar graph
represents SPTLC1 band intensity normalized to actin (four independent experiments). The SPTLC1/actin ratio of untreated cells (c) was set to 1 and the mean OD ratios are
displayed numerically. One representative blot is shown as inset. (C) Untreated cells (control) or cells treated with vehicle (DMSO; vc) or myriocin under serum-free
conditions were counted at the indicated times. Results shown represent mean  SD from triplicate experiments. *p < 0.05 compared to vehicle control (one-way ANOVA). (D)
Ceramide and (E) sphingomyelin composition was quantitated by LC–MS analysis in vehicle (vc) or myriocin-treated cells as described in Fig. 1C and D. Results represent mean  SD
from triplicate experiments. Cer and SM species are displayed on basis of their acyl chain composition. (F) Cells were incubated overnight in medium containing DMSO as vehicle
control (vc) or myriocin (1 mM). S1P levels of cell lysates were determined using a competitive ELISA. Data are presented as mean  SEM (two independent experiments performed
in duplicates). Unpaired Student’s t-test was used for analysis of statistical signiﬁcance. *p < 0.05 compared to vehicle.
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myriocin [42]. These experiments were performed in serum-free
medium. Under these conditions U87MG cells still proliferate
although approx. twofold slower than in serum-containing
medium (Fig. 2A). Myriocin tended to increase SPTLC1 protein
levels (up to 1.6-fold at 5 mM; Fig. 2B). Pharmacological inhibition
of SPT reduced cell numbers by 55 and 75% at day 5 (1 and 5 mM
myriocin; Fig. 2C). Myriocin treatment led to statistically signiﬁ-
cant reduction of the C16:0, 18:1, 18:2, 22:1, 24:0, and 24:1 Cer
species (Fig. 2D; 73 vs. 121 ng/mg cell protein) and also decreased
the content of several SM species (Fig. 2E; total SM
content = 3062 vs. 4706 ng/mg cell protein; myriocin- vs. vehi-
cle-treated cells). Finally, myriocin treatment induced a signiﬁcant
decrease of intracellular S1P concentrations by 35% (Fig. 2F).
To study whether reduced cell proliferation due to RNAi or
myriocin is accompanied by apoptosis, Annexin V-FITC (A)/PI
staining was performed (Fig. 3). Under non-treated conditions the
number of early and late apoptotic cells was 11 and 8%,composition was analyzed in U87MG cells and quantitated by LC–MS/MS analysis in control c
C-18 UPLC-column, and analyzed with a QTOF-MS system. Data analysis was performed 
experiments. Cer and SM species are displayed on basis of their acyl chain composition.respectively (Fig. 3A; upper panel). Mock transfection with
Oligofectamine was without effect on cell viability. Silencing of
SPTLC1 increased the percentage of late apoptotic cells (16 and
20%; siSPTLC_12 and _13, respectively; Fig. 3A, upper panel). In
comparison, 31% of myriocin-treated cells were early and 19% late
apoptotic (Fig. 3A; lower panel). Also DMSO used as vehicle control
increased the percentage of early and late apoptotic cells (21 and
11%, respectively). Fig. 3B summarizes the percentage of living,
early and late apoptotic, and A/PI+ cells. To get an indication
about underlying pathways Western blot analysis of silenced and
myriocin-treated cells was performed. Results of these experi-
ments (Fig. 3C) revealed upregulation of p53 and p21 in silenced
(and to a lower extent in myriocin-treated) cells, indicating a pro-
apoptotic role of these tumor suppressors when de novo SL
synthesis is inhibited. Statistical evaluation of p53 and p21 band
intensities is shown in Fig. 3D and E.
The SPT subunits SPTLC1, -2, and -3 are approx. equally
expressed by U87MG cells on mRNA level (Fig. 4A). To examine theells or cells transfected with siScr or siSPTLC1_13. Lipids were extracted, separated on a
using the Lipid Data Analyzer Software. Results represent mean  SD from triplicate
Fig. 3. Genetic and pharmacological inhibition of SPT induces apoptosis. (A) U87MG cells were either untransfected or transfected with Oligofectamine (mock) or SPTLC1-
targeting siRNAs (day 5; upper panel). Control cells, vehicle- and myriocin-treated cells (1 mM, day 5) are shown in the lower panel. The cells were trypsinized, stained with
Annexin V-FITC (A) and propidium iodide (PI) and analyzed by ﬂow cytometry. Cells in the lower right quadrant represent A+/PI early apoptotic cells and these in the upper
right quadrant (A+/PI+) represent late apoptotic cells. To set up ﬂuorescent compensation and gating, unstained and single stained positive controls (1 mM staurosporine or
3 mM H2O2, 4 h) were used. Untreated (control), mock transfected (mock), SPTLC1-silenced, DMSO (vehicle control) and myriocin (1 mM)-treated cells were analyzed. (B) The
bar graph shows the proportion of A/PI (living), A+/PI (early apoptotic), A+/PI+ (late apoptotic), and A/PI+ cells from two independent experiments performed in
triplicates. (C) The effects of SPT inhibition using RNAi (siSPTLC1_12, _13) and myriocin on SPTLC1, p53, p21, and b-actin expression were analyzed by Western blotting.
Following densitometric Western blot analysis p53 (D) and p21 (E) band intensities were normalized to actin (four independent experiments). The p53- and p21/actin ratio of
untreated cells (c1 = silencing-, c2 = myriocin-controls) was set to 1 and the mean OD ratios are displayed numerically. One representative blot is shown as inset.
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Fig. 4. Characterization of SPTLC family member expression and silencing effects on U87MG proliferation. (A) SPTLC subunit expression by U87MG cells grown under standard
conditions was analyzed by RT-qPCR. Target gene expression was normalized to HPRT. Gene expression ratios were calculated by REST as described in Materials and Methods.
SPTLC1 expression was arbitrarily set to 1. (B) At day 3 post-silencing SPTLC1, -2, and -3 RNA levels were quantitated by RT-qPCR. Target gene expression in silenced cells was
normalized to target gene expression in mock transfected cells. Gene expression ratios were calculated by REST as described in Materials and Methods. (C) Following
knockdown of the indicated SPTLC family members cell numbers were counted at the indicated time points. Results shown represent mean  SD from triplicate experiments.
Untreated cells (control, ‘c’) and cells transfected with scrambled siRNA (siScr) were used as controls. *p < 0.05, **p < 0.01, ***p < 0.001 compared to siScr (one-way ANOVA).
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silenced also SPTLC2 and -3 and performed a co-silencing
approach. Silencing efﬁcacy (determined by qPCR) was between
57 and 79% (Fig. 4B). Also the double (SPTLC1/2 and SPTLC1/3) and
triple (SPTLC1/2/3) silencing approaches resulted in efﬁcient
knockdown. However, silencing of the other SPT subunits (SPTLC2
and -3) either alone or in combination (SPTLC1/2; SPTLC1/3, and
SPTLC1/2/3) did not further decrease cell numbers as compared to
single SPTLC1 knockdown (Fig. 4C).
3.2. The contribution of S1P receptors to U87MG proliferation
Having established that silencing or inhibition of SPT impacts
on SL, S1P content, and cell viability the role of individual S1P
receptors that transmit S1P-dependent growth signals was
investigated. Under basal conditions highest mRNA levels were
observed for S1P3 (S1P3/HMBS = 9), followed by S1P2 and S1P1; the
latter was arbitrarily set to 1 (Fig. 5A). Lowest expression was
found for S1P5 while no S1P4 could be detected on RNA level. The
molecular masses (Western blotting) of S1P receptors present on
U87MG cells were 55 (S1P1), 45 (S1P2), 52 and 55 (S1P3), 40 and 50
(S1P5) kDa (Fig. 5B, lane 1). The pattern of immunoreactive bands
for S1P receptors in HeLa cells (Fig. 5B, lane 2), used as controls,
was comparable to U87MG. In contrast immunoreactive bands in
mouse brain protein lysates (Fig. 5B, lane 3) were detected at
28 and 50 kDa using S1P1 and S1P5 antibodies, respectively.
To get an indication about the quantitative contribution of
individual S1P receptors to U87MG cell proliferation we used RNAi.
This approach was applied to clarify silencing efﬁcacies and
potential off-target or counter-regulatory effects on non-targeted
S1P receptors on mRNA level (Fig. 5C–F). In general, silencing was
efﬁcient and mRNA levels of targeted receptors were down-
regulated between 70 and 90%. Silencing of S1P1 was withoutpronounced effects on expression levels of non-targeted receptors
(Fig. 5C). In contrast, silencing of S1P2, S1P3, and S1P5 was
paralleled by up-regulation of S1P1 between two- and ﬁvefold
(Fig. 5D–F). Silencing of S1P5 (Fig. 5F) induced transcriptional
upregulation of S1P2 and S1P3 at day 3 post silencing.
Next, effects of S1P receptor subtype silencing on U87MG
proliferation was studied. These data (Fig. 5G) showed that all S1P
receptors impact on U87MG proliferation, though to different
degrees: S1P1 silencing induced a reduction in cell numbers (day
5 post silencing) by 45%. S1P2 knockdown resulted in growth
inhibition by 30%. Knockdown of S1P3 and S1P5 reduced cell
numbers by 63 and 50%. In light of counter-regulations identiﬁed
in Fig. 5D–F it was not possible to unambiguously identify the
receptor with the highest impact on U87MG proliferation.
The majority of physiologically active S1P (that promotes S1P
receptor-mediated downstream signaling) is transported in
association with albumin and/or HDL [43]. Therefore the effects
of these physiological S1P carriers on cell proliferation were
studied. Exogenous S1P at physiologically relevant concentrations
(10 nM to 1 mM; Ref. [44]) led to increased U87MG cell
proliferation (Fig. 5H). While BSA-complexed S1P increased cell
numbers by a maximum of 1.4-fold, HDL-associated S1P enhanced
proliferation rates by a maximum of 1.8-fold in comparison to
vehicle-treated cells.
3.3. ABCA1 is a potential contributor to S1P inside out signaling
Finally we sought evidence whether ABCA1 could contribute to
S1P efﬂux in U87MG cells, a mechanism reported for non-
transformed astrocytes [31]. U87MG cells express ABCA1 and
addition of exogenous S1P slightly increased ABCA1 levels
(Fig. 6A). In contrast, a synthetic liverXreceptor (LXR) ligand
(TO901317) and the natural LXR ligands 24- and 25-OHcholesterol
Fig. 5. S1P receptor expression and silencing. (A) S1P receptor subtype expression by U87MG cells grown under standard conditions was analyzed by RT-qPCR. Target gene
expression was normalized to HMBS. Gene expression ratios were calculated by REST as described in Materials and Methods. S1P1 expression was arbitrarily set to 1. (B) S1P
receptor subtype expression by U87MG cells (lane 1), HeLa cells (lane 2) and mouse brain protein lysates (lane 3) was analyzed by Western blotting. Molecular masses are
indicated. (C–F) Effect of S1P receptor knockdown on mRNA levels of targeted and non-targeted receptor family members. Receptor silencing was performed with siRNA
constructs showing highest silencing efﬁcacy in a pre-screen. Relative gene expression of target genes (as analyzed by real time qPCR) at days 3 and 5 (d3, d5) post silencing is
presented in relation to HMBS. Results represent mean  SD from three independent experiments. (G) Effect of S1P receptor silencing on cell proliferation. Individual S1P
receptors were silenced as described above. Cells were counted at days 3 and 5 post silencing. Untreated cells (control) and cells transfected with Oligofectamine (mock) or
scrambled siRNA (siScr) were used as controls. Results are cell numbers normalized to day zero and represent mean  SD from triplicate determinations. (H) Effects of exogenously
added S1P on cell proliferation. Cells were grown in the absence (c) or the presence of the indicated S1P concentrations complexed either to BSA (BSA-S1P) or HDL (HDL-S1P). After
ﬁve days cells were washed, trypsinized and counted. Results represent mean  SD from two independent experiments done in triplicates. Vehicle control (‘carrier’) consisting of
BSA or HDL (‘carrier-S1P’). *p < 0.05, **p < 0.01, ***p < 0.001 compared to the corresponding vehicle control (unpaired Student’s t-test).
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ABCA1 reduced protein levels between 30 and 60% (Fig. 6B) and
inhibited cell proliferation by 50 and 65% (Fig. 6C). Comparable
results were obtained with pharmacological ABCA1 antagonists(glyburide and DIDS) that reduced cell numbers by approx. 40%
(Fig. 6D). Cell lysates from glyburide-treated cells revealed S1P
concentrations 2.7-fold higher as compared to vehicle-treated
cells (Fig. 6E) indicating reduced S1P efﬂux in response to
Fig. 6. Silencing and pharmacological inhibition of ABCA1 reduces U87MG proliferation and increases intracellular S1P concentrations. (A) Expression of ABCA1 was
determined in cells cultured in the absence (‘c’) or the presence of a synthetic LXR ligand (TO901317; 10 mM; ‘TO’), S1P (1 mM), or natural LXR ligands (24-OHcholesterol; ‘24-
OH’; 1 mM; 25-OHcholesterol; ‘25-OH’; 1 mM). After 3 days cellular lysates were analyzed by Western blotting. The bar graph represents ABCA1 band intensity normalized to
actin (three independent experiments). The ABCA1/actin ratio of untreated cells (c) was set to 1 and the mean OD ratios are displayed numerically. One representative blot is
shown as inset. (B) ABCA1 expression was analyzed in untreated (c) cells and cells subjected to transfection with Oligofectamine (mock), scrambled siRNA (siScr), and two
ABCA1 siRNAs (si1_2 and si1_5). The bar graph represents ABCA1 band intensity normalized to actin (three independent experiments) and mean OD are displayed
numerically. The ABCA1/actin ratio of untreated cells (c) was set to 1 and the mean OD ratios are displayed numerically. One representative blot is shown as inset. (C)
Untreated cells (control) and cells subjected to transfection with Oligofectamine (mock), scrambled siRNA (siScr), and two ABCA1 siRNAs (si1_2 and si1_5) were harvested at
days 3 and 6 post silencing and counted. Results are cell numbers normalized to day zero and represent mean  SD of triplicate dishes. (D) ABCA1 was pharmacologically
inhibited with glyburide (200 mM, in DMSO) or DIDS (400 mM in PBS). After three days cells were washed, trypsinized and counted. Results represent mean  SD from triplicate
dishes. ***p < 0.001 compared to vehicle controls (control = untreated, vc1 = DMSO, vc2 = PBS). (E) Cells were incubated for 24 h in medium containing DMSO (vc) in the absence or
the presence of glyburide (500 mM for 10 h followed by 200 mM for 14 h). S1P concentrations of cellular lysates were determined using a competitive ELISA. Data are presented as
mean  SEM (two independent experiments performed in triplicate). Unpaired Student’s t-test was used for analysis of statistical signiﬁcance. **p < 0.01 compared to vehicle
control. 100% of S1P corresponds to 221 pmol/mg cell protein. (F) Cells were incubated for 24 h in the absence (control) or the presence of glyburide (200 mM), DIDS (400 mM), or the
corresponding vehicles (DMSO or PBS, vc1 and vc2, respectively). Where indicated, cells received (in addition to glyburide or DIDS) S1P (1 mM). After three days cells were washed,
trypsinized and counted. Results represent mean  SD from triplicate dishes. **p < 0.01, ***p < 0.001 compared to the corresponding vehicle control (one-way ANOVA).
E. Bernhart et al. / Biochemical Pharmacology 96 (2015) 119–130 127pharmacological ABCA1 antagonism. Addition of exogenous S1P
reverted the proliferative block mediated by glyburide and DIDS
(Fig. 6F). These ﬁndings suggest that genetic or pharmacological
interference with S1P efﬂux holds promise to inhibit cancer cell
proliferation.
4. Discussion
The present study aimed to interfere with key synthetic and
signaling nodes of SL turnover in U87MG glioma cells. The present
in vitro data suggest that interference with de novo SL synthesis,
signaling via S1P receptors, or efﬂux of S1P (ABCA1) attenuates
U87MG glioma cell proliferation.To investigate the impact of de novo SL biosynthesis on
proliferative behavior we have modulated the expression or
activity of a key enzyme involved in this pathway. SPTLC1 and the
heterodimer formed with SPTLC2 or SPTLC3 constitutes the
catalytic core of the enzyme. RNAi of SPTLC1 was efﬁcient and
downregulated proliferation of GBM2 and U87MG glioma cells that
express p53wt, but was without effect on GM133 and U251MG,
that express p53mut (Fig. 1). All of the remaining experiments were
performed with p53wt U87MG cells. Inhibition of SPT with
myriocin reduced cell numbers by 40–70% (Fig. 2). This is
comparable to what was reported for myriocin-induced cell cycle
arrest in lymphocytes: In that study [45] myriocin reduced
proliferation by approx. 50%.
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by 37% with the quantitatively most pronounced changes seen in
C16:0, C24:0, and C24:1 while the SM composition was almost
unaffected (Fig. 1C and D). Surprisingly, transfection with siScr also
diminished the cellular Cer content (Fig. 1C); currently the reason
for this observation is not clear. In response to myriocin the
quantitatively most pronounced decrease was observed for C24:0
Cer (Fig. 2D). In contrast to the siRNA approach myriocin induced
also a decline in most SM species (Fig. 2E). Pharmacological
manipulation of SL metabolism in tumor cells holds promise as
new therapeutic modality in cancer. However, tuning the SL
rheostat in the direction of Cer synthesis might be insufﬁcient
since some cancer types like endometrial cancer [46], breast tumor
biopsies [47], or murine xenografts [48] have higher Cer content as
compared to non-transformed tissue.
Therefore we decided to inhibit de novo SL biosynthesis to
interfere with glioma cell proliferation. Feasibility of such an
approach was demonstrated in melanoma, where myriocin
treatment induced growth arrest in vitro [49] and suppressed
tumor growth in a murine melanoma model via p53- and p21-
dependent pathways [50] as observed during the present study
(Fig. 3C–E). This might be of importance for future studies since
SPTLC1 silencing was without effect on GBM cell proliferation that
express p53mut (Fig. 1B). In liver cells silencing of the SPTLC
subunits 1–3 reduced Cer levels by approx. 35% [51], comparable to
what we have found in U87MG cells (Fig. 1C). Of note, SPTLC1
silencing had the most pronounced effects on cell proliferation
during the present study (Fig. 4). SPTLC silencing impacted global
gene expression with upregulation of negative regulators of
biosynthetic processes demonstrating the possibility of energy
deprivation in response to decreased Cer synthesis [51]. In the
intestine, conditional knockout of SPTLC2 induced necrotic lesions
at the bases of villi and crypts, indicating the requirement for de
novo Cer biosynthesis via SPT during proliferation [52]. Finally, Cer
is the central metabolite of SL turnover and it is conceivable that
membrane synthesis, architecture, and function could be pro-
foundly disturbed under Cer-depleted conditions [53].
There is consensus that Cer species with speciﬁc acyl chain
length may have unique cellular functions [54]. In terms of species
speciﬁcity it was shown that C18:0 Cer induces cancer cell death
and decreases tumor growth [55]. In contrast, C16:0 (which is
increased in glioma; Ref. [19]) and C24:0 Cer can increase cancer
cell proliferation and protect from cell death [56]. Knockdown of
CerS2 (the Cer synthase member catalyzing C24 Cer formation) in
HeLa cells resulted in nearly complete absence of C22 and C24 Cer
species and signiﬁcantly enhanced sensitivity toward cisplatin-
induced apoptosis [57]. Thus, a reduction in C16:0 and/or C24:0
Cer as observed during the present study (Figs. 1C and 2D) could
account for reduced cell viability of U87MG cells where SPT
function was genetically or pharmacologically inhibited. However,
it remains to be determined whether changes in the composition of
SL chain length affect apoptosis signaling directly or indirectly, e.g.
via changes in membrane properties such as microdomain
formation. Another possibility that was not addressed here is
reduced formation of pro-proliferative Cer-1-P [58] as a conse-
quence of substrate shortage in SPTLC-silenced or myriocin-
treated glioma cells. Finally, ceramides are capable of inducing
either survival or lethal autophagy (reviewed in [54]), however,
these pathways were not followed up during the present study.
Pharmacological inhibition of SPT with myriocin reduced the
intracellular S1P concentrations (Fig. 2F). S1P-dependent signaling
networks are elicited by the corresponding S1P receptors. RT-qPCR
and Western blot analysis revealed expression of S1P1–3,5 on
U87MG cells (Fig. 5). This is in line with S1P receptor expression
patterns identiﬁed in human GBM tissue [20,21]. Van Brocklyn
and Young [24] reported that S1P1–3 contribute to U-118MG andU-373MG glioma cell proliferation, with S1P1 being the most
important regulator. These authors [24] reported that S1P3 and
S1P1 mediate glioma cell migration and invasion. High expression
of S1P1 correlates with high invasive potential of CD133
+ GBM cells
[15,16]. S1P2 inhibits GBM cell migration [22–24] but upregulates
their invasive potential [24]. Our ﬁnding that S1P1was consistently
upregulated in response to S1P2, S1P3 and S1P5 silencing (Fig. 5C–
F) deserves attention. Although the ability of S1P receptors to
homo- and heterodimerize is established [59,60], it is currently not
clear whether functional loss of one binding partner could induce
transcriptional regulation of the other.
Finally we showed that silencing or inhibition of ABCA1
decreased U87MG proliferation. ABCA1 expression in U87MG
cells was potently induced by 25-OHcholesterol (Fig. 6A), a natural
LXR ligand and oxysterol synthesized and secreted by glioma cells
[61]. This supports the notion that oxysterol synthesis provides an
autocrine signal that enhances ABCA1 expression thereby increas-
ing S1P export from glioma cells. Of note, glyburide induced
accumulation of intracellular S1P and exogenously added S1P
partially restored cell proliferation in the presence of ABCA1
inhibitors (Fig. 6F). These ﬁndings would be compatible with
reduced ABCA1-dependent efﬂux of this bioactive lipid mediator in
U87MG glioma cells. However, the ABCA1 transporter actively
transports also other lipids, namely cholesterol, phosphatidylcho-
line, phosphatidylserine, and SM [62]. Therefore pharmacological
antagonism or silencing of ABCA1 could result in chronic exposure
to high concentrations of intracellular cholesterol that compro-
mise (U87MG) cell viability. The fact that exogenously added S1P
to DIDS- and glyburide-treated cells only partially restored cell
proliferation (Fig. 6F) could substantiate the existence of such a
mechanism.
In addition to other S1P transporters [63], ABCA1 plays a critical
role in S1P efﬂux to newly synthesized HDL-like particles in
astrocytes [31]. Noteworthy, in a patient cohort of type 2 diabetes
mellitus glyburide treatment was associated with reduced cancer
risk [64]. In animal models glyburide (in combination with CoCl2)
inhibited the growth of breast cancer xenografts [65]. In vitro,
glyburide was shown to induce G0/G1 arrest in breast cancer cells
[66] and to suppress invasive properties of ovarian carcinoma cells
[67]. Finally, high expression of ABCA1 (and other members of the
ABCA family) correlates with reduced survival in serous ovarian
cancer patients and siRNA-mediated suppression of ABCA1
inhibited ovarian cancer cell growth and migration in vitro [68].
Overall, data presented here identify de novo SL biosynthesis, as
well as S1P outside-in and inside-out signaling as attractive
pathways to interfere with proliferation in GBM cells expressing
p53wt. However, the clinical situation might be more complex,
especially in terms of altered SL synthesis/turnover in response to
chemo- and/or radiation therapy.
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